Biodesix partners with Thermo Fisher Scientific on blood-based cancer test

Wednesday July 10, 2019 0 comments Tags: Boulder, Biodesix, Thermo Fisher Scientific, David Brunel

BOULDER -- Biodesix, Inc, a leader in blood-based lung cancer diagnostic solutions, announced it has entered into an agreement with Thermo Fisher Scientific designed to bring a blood-based next-generation sequencing (NGS) assay to market with premarket approval (PMA) classification from the U.S. Food and Drug Administration (FDA).Biodesix_logoUSE

Biodesix said it will work to develop all required analytical and clinical data using Thermo Fisher’s Ion Torrent Oncomine Pan-Cancer Cell-Free Assay in an effort to obtain regulatory approval from the FDA. The program will focus on an NGS-based solution for patients with advanced non-small cell lung cancer (NSCLC).

Upon FDA approval, Biodesix said it will have a single-site PMA (ssPMA) for an NGS liquid biopsy covering actionable markers in cancer. The designation will extend Biodesix collaborations with biopharmaceutical companies for NGS-based biomarker discovery, validation studies, and commercialization capabilities that include regulatory approval and reimbursement for companion diagnostics.

The Ion Torrent Oncomine Pan-Cancer Cell-Free Assay enables reproducible detection and analysis of tumor DNA and RNA across all major classes of somatic mutations (SNVs, indels, CNVs and fusions) from a single vial of blood within two days.

Targeting 52 genes across multiple cancer types, including lung, colorectal, breast, pancreatic, thyroid and others, the cell-free total nucleic acid (cfTNA) assay has broad application for liquid biopsy clinical research applications, Biodesix said.

“We are dedicated to providing actionable answers that physicians and patients need by leveraging the best technology available,” said David Brunel, Biodesix CEO.

“Building on our expertise in blood-based solutions, this assay will expand our lung cancer portfolio to provide physicians and biopharmaceutical companies with blood-based NGS assays that provide fast turn around and comprehensive answers.

“This agreement enables Biodesix to continue innovating much needed cancer diagnostic solutions that service clinical and biopharma partners from early discovery through global distribution.”